Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

Nature

Volumn 508, Issue 7496, 2014, Pages 402-405

  Warren, Travis K ^a   Wells, Jay ^a   Panchal, Rekha G ^a   Stuthman, Kelly S ^a   Garza, Nicole L ^a   Van Tongeren, Sean A ^a   Dong, Lian ^a   Retterer, Cary J ^a   Eaton, Brett P ^a   Pegoraro, Gianluca ^a   Honnold, Shelley ^a   Bantia, Shanta ^b   Kotian, Pravin ^b   Chen, Xilin ^b   Taubenheim, Brian R ^b,d   Welch, Lisa S ^a   Minning, Dena M ^c   Babu, Yarlagadda S ^b   Sheridan, William P ^b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

^c MedExpert Consulting Inc   (United States)

^d Wilco Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BCX 4430; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG; VIRUS RNA;

DISEASE INCIDENCE; DRUG DEVELOPMENT; HEALTH CARE; INFECTIVITY; PUBLIC HEALTH; RNA; VIRAL DISEASE; VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; BUNYAVIRUS; CONTROLLED STUDY; CORONAVIRUS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FILOVIRIDAE; FILOVIRUS; FILOVIRUS INFECTION; FLAVIVIRUS; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; INFECTION CONTROL; MARBURG HEMORRHAGIC FEVER; NONHUMAN; ORTHOMYXOVIRUS; PARAMYXOVIRUS; PICORNAVIRUS; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RAT; RIFT VALLEY FEVER BUNYAVIRUS; TOGAVIRUS;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MACACA; MARBURGVIRUS; ORTHOBUNYAVIRUS; PRIMATES; RODENTIA;

ADENOSINE; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA-DIRECTED RNA POLYMERASES; EBOLAVIRUS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HEMORRHAGIC FEVER, EBOLA; HUMANS; INJECTIONS, INTRAMUSCULAR; MACACA FASCICULARIS; MARBURG VIRUS DISEASE; MARBURGVIRUS; PURINE NUCLEOSIDES; RNA; TIME FACTORS;

EID: 84899439262     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13027     Document Type: Article

References (29)

1. Kuhn, J. H. Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies (Springer, 2008
2. Bausch, D. G. et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 196 (suppl. 2), S142-S147 (2007
3. Kortepeter, M. G., Bausch, D. G. & Bray, M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 204 (suppl. 3), S810-S816 (2011
4. Towner, J. S. et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 4, e1000212 (2008
5. Geisbert, T. W. et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26, 6894-6900 (2008
6. Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375, 1896-1905 (2010
7. Warfield, K. L. et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196 (suppl. 2), S430-S437 (2007
8. Warren, T. K. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature Med. 16, 991-994 (2010
9. Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl Acad. Sci. USA 109, 5034-5039 (2012
10. Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y. & Nabel, G. J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609 (2000
11. Huggins, J. W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11 (suppl. 4), S750-S761 (1989
12. Smither, S. J. et al. Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. http:// dx.doi.org/10.1016/j.antiviral.2014.01.012 (2014
13. Aman, M. J. et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 83, 245-251 (2009
14. Bray, M., Driscoll, J. & Huggins, J. W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-Adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res. 45, 135-147 (2000
15. Bray, M., Raymond, J. L., Geisbert, T. & Baker, R. O. 3-Deazaneplanocin A induces massively increased interferon-A production in Ebola virus-infected mice. Antiviral Res. 55, 151-159 (2002
16. Kinch, M. S. et al. FGI-104: A broad-spectrum small molecule inhibitor of viral infection. Am. J. Transl. Res. 1, 87-98 (2009
17. Panchal, R. G. et al. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Res. 93, 23-29 (2012
18. Warren, T. K. et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob. Agents Chemother. 54, 2152-2159 (2010
19. Hevey, M.,Negley, D., Pushko, P.,Smith, J.& Schmaljohn, A.Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251, 28-37 (1998
20. Kobinger, G. P. et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J. Infect. Dis. 204, 200-208 (2011
21. Bente, D., Gren, J., Strong, J. E. & Feldmann, H. Disease modeling for Ebola and Marburg viruses. Dis. Model. Mech. 2, 12-17 (2009
22. Smith, D. H. et al. Marburg-virus disease in Kenya. Lancet 319, 816-820 (1982
23. Panchal, R. G. et al. Development of high-content imaging assays for lethal viral pathogens. J. Biomol. Screen. 15, 755-765 (2010
24. Barnard, D. L. et al. Inhibition of measles virus replication by 59-nor carbocyclic adenosine analogues. Antivir. Chem. Chemother. 12, 241-250 (2001
25. Mühlberger, E.,Weik, M., Volchkov, V. E., Klenk, H. D.& Becker, S. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73, 2333-2342 (1999
26. Lou, H., Choi, Y. H., LaVoy, J. E., Major, M. E. & Hagedorn, C. H. Analysis of mutant NS5B proteins encoded by isolates from chimpanzees chronically infected following clonal HCV RNA inoculation. Virology 317, 65-72 (2003
27. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. & Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651-661 (1998
28. Warfield, K. L. et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J. Virol. 83, 6404-6415 (2009
29. Alves, D. A. et al. Aerosol exposure to the Angola strain of Marburg virus causes lethal viral hemorrhagic fever in cynomolgus macaques. Vet. Pathol. 47, 831-851 (2010